CYAD-221

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameCYAD-221
Drug Alias Nameanti-CD19 CAR T-cell therapy (Celyad Oncology)anti-CD19 shRNA CAR T-cell therapy (Celyad Oncology)anti-CD19 CAR T-cell therapy (Celyad Oncology)non-gene edited anti-CD19 CAR T-cell therapy (Celyad Oncology)CYAD-221
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgium
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCelyad Oncology SA
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCelyad Oncology SA
Active IndicationsN/A
Inactive IndicationsLymphoma, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A